An Evaluation of the Safety of Lamivudine in HIV Positive Patients with Renal Impairment (208948)

Study identification

• EU PAS number:
  EUPAS27718
• Study ID:
  40815
• Official title and acronym:
  An Evaluation of the Safety of Lamivudine in HIV Positive Patients with Renal Impairment (208948)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  No information provided.
• Study status:
  Finalised

Research institutions and networks

Institutions

ViiV Healthcare

Study timelines

Date when funding contract was signed

Planned:14/12/2017

Actual:14/12/2017

Study start date

Planned:30/05/2019

Actual:14/02/2019

Date of final study report

Planned:30/08/2019

Actual:18/09/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

ViiV Healthcare

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable